The effect of Telehealth on community delivered diabetes care: a cross sectional study

Does blood glucose telemonitoring (Tm) and remotely delivered lifestyle advice improve self management in Type 2 Diabetes (T2DM)? A cross-sectional study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51677359

Enrollment

800

Registered

2014-03-11

Start date

2014-03-01

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

Study subjects will be connected to the backend monitoring via a usual primary care visit and set up through Florence©, Simple Telehealth, Web-based monitoring system (Stoke on Trent, NHS England) (ww

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of T2DM 2. Currently using self monitoring blood glucose monitors 3. Capability to use Tm and mobile phones including for the use of text messaging 4. Cognitively able to provide informed consent 5. Aged more than 18 years

Exclusion criteria

Exclusion criteria: 1. Unwilling or unable to provide written consent 2. Lack of mobile phone signal where they reside normally 3. Clincian's discretion based on behaviour, social circumstances etc.

Design outcomes

Primary

Measure	Time frame
Number of face-to-face primary care contacts between the Intervention and Comparator Groups over 12 months	—

Secondary

Measure	Time frame
Assessed 12 months after recruitment 1. Health data: 1.1 HbA1c level 2. Health contacts: 2.1. Number of admissions to secondary care 2.2. Number of bed days 2.3. Number of emergency room visits 2.4. Number of elective and emergency visits to GPs and primary health care 2.5. Number of specialist nurse home visits 2.6. Number of clinic visits to secondary care 3. Other outcomes: 3.1. Cost per avoided face-to-face primary care contact 3.2. Qualitative reporting of the barriers to implementing Tm 3.3. Adverse events attributed to Tm 4. Organisational outcomes: 4.1.To determine whether the required organisational changes can be implemented at scale and in a timely fashion. The Tm will result in a workload for the staff involved that is acceptable to them. 4.2. The required organisational changes and new ways of working are agreed and approved by the appropriate management structures within the relevant agencies involved in the delivery. 4.3. The intervention models can be successfully transferred to other regions and mainstreamed as part of usual care. 5. Economic outcomes To evaluate the cost-effectiveness of Tm in aT2DM care pathway. 6. Other outcomes To determine if a new Tm service is acceptable to all stakeholders including patients and health professionals.	—

Measure

Time frame

Assessed 12 months after recruitment 1. Health data: 1.1 HbA1c level 2. Health contacts: 2.1. Number of admissions to secondary care 2.2. Number of bed days 2.3. Number of emergency room visits 2.4. Number of elective and emergency visits to GPs and primary health care 2.5. Number of specialist nurse home visits 2.6. Number of clinic visits to secondary care 3. Other outcomes: 3.1. Cost per avoided face-to-face primary care contact 3.2. Qualitative reporting of the barriers to implementing Tm 3.3. Adverse events attributed to Tm 4. Organisational outcomes: 4.1.To determine whether the required organisational changes can be implemented at scale and in a timely fashion. The Tm will result in a workload for the staff involved that is acceptable to them. 4.2. The required organisational changes and new ways of working are agreed and approved by the appropriate management structures within the relevant agencies involved in the delivery. 4.3. The intervention models can be successfully transferred to other regions and mainstreamed as part of usual care. 5. Economic outcomes To evaluate the cost-effectiveness of Tm in aT2DM care pathway. 6. Other outcomes To determine if a new Tm service is acceptable to all stakeholders including patients and health professionals.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026